Back to results
US 9,872,900 B2Granted
Nucleic acid vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
Claims26
A nucleic acid vaccine, comprising:
- one or more RNA polynucleotides having an open reading frame encoding a hemagglutinin protein selected from H1, H7 and H10 wherein the hemagglutinin protein is derived from a strain of Influenza A virus, wherein the RNA polynucleotide includes a chemical modification and a pharmaceutically acceptable carrier or excipient, formulated within a lipid nanoparticle, wherein the lipid nanoparticle has about 20-60 mol % ionizable cationic lipid;
- about 5-25 mol % non-cationic lipid;
- about 25-55 mol % sterol;
- and about 0.5-15 mol % PEG-modified lipid.
1 more element
A nucleic acid immunogenic composition, comprising:
- one or more RNA polynucleotides having an open reading frame encoding a hemagglutinin protein selected from H1, H7 and H10 wherein the hemagglutinin protein is derived from a strain of Influenza A virus, wherein the RNA polynucleotide includes a chemical modification and a pharmaceutically acceptable carrier or excipient, formulated within a lipid nanoparticle, wherein the lipid nanoparticle has about 20-60 mol % ionizable cationic lipid;
- about 5-25 mol % non-cationic lipid;
- about 25-55 mol % sterol;
- and about 0.5-15 mol % PEG-modified lipid.
1 more element
Dependencies are inferred from the claim text.